<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2024-34-5-40-46</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-1355</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Отсутствие тканевого вирусологического ответа как предиктор рецидива хронического гепатита D после завершения терапии булевиртидом</article-title><trans-title-group xml:lang="en"><trans-title>Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2346-1216</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богомолов</surname><given-names>П. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogomolov</surname><given-names>P. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богомолов Павел Олегович — кандидат медицинских наук, руководитель отделения и ведущий научный сотрудник гепатологического отделения, МОНИКИ им. М.Ф. Владимирского; доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии, МГМСУ им. А.И. Евдокимова.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Pavel O. Bogomolov — Cand. Sci. (Med.), Head of the Department and Leading Researcher of the Hepatological Department, MRRCI (“MONIKI”); Associate Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Evdokimov MSU of Medicine and Dentistry.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">bpo73@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6865-8210</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шуб</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shub</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шуб Надежда Анатольевна — заместитель главного врача по экономическим вопросам.</p><p>125008, Москва, ул. Большая Академическая, 39, корп. 3</p></bio><bio xml:lang="en"><p>Nadezhda A. Shub — Deputy Chief Physician for Economic Affairs</p><p>125008, Moscow, Bolshaya Akademicheskaya str., 39, build. 3</p></bio><email xlink:type="simple">nadya.shub@icloud.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-7527-5918</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гасилова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gasilova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гасилова Наталья Александровна — заведующая лабораторией молекулярной диагностики клинико-диагностической лаборатории «ИНВИТРО-Москва».</p><p>105037, Москва, ул. 2-я Прядильная, 1</p></bio><bio xml:lang="en"><p>Natalia A. Gasilova — Head of the Laboratory of Molecular Diagnostics of the Clinical Diagnostic Laboratory “INVITROMoscow”.</p><p>105037, Moscow, 2-ja Prjadilnaya str., 1</p></bio><email xlink:type="simple">NGasilova@invitro.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-3031-7189</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белякова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyakova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белякова Анна Александровна — кандидат медицинских наук, врач клинической лабораторной диагностики, ООО «Независимая лаборатория ИНВИТРО».</p><p>121059, Москва, ул. Киевская, 9/2, пом. 1</p></bio><bio xml:lang="en"><p>Anna А. Belyakova — Cand. Sci. (Med.), Doctor of Clinical Laboratory Diagnostics.</p><p>121059, Moscow, Kievskaya str., 9/2, room 1</p></bio><email xlink:type="simple">abelyakova@invitro.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-1279-6885</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиджиева</surname><given-names>Ц. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Lidzhieva</surname><given-names>T. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лиджиева Цаган Гаряевна — врач клинической лабораторной диагностики.</p><p>121059, Москва, ул. Киевская, 7/2, пом. 1</p></bio><bio xml:lang="en"><p>Cagan G. Lidzhieva — Doctor of Clinical Laboratory Diagnostics.</p><p>121059, Moscow, Kievskaya str., 7/2, room 1</p></bio><email xlink:type="simple">tglidzhieva@invitro.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8240-5452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кондрашева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kondrasheva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кондрашева Елена Анатольевна — директор департамента лабораторных технологий.</p><p>121059, Москва, ул. Киевская, 9/2, пом. 1</p></bio><bio xml:lang="en"><p>Elena A. Kondrashеva — Director of the Laboratory Technology Department.</p><p>121059, Moscow, Kievskaya str., 9/2, room 1</p></bio><email xlink:type="simple">ekondrashova@invitro.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1892-2508</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барсукова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Barsukova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барсукова Наталья Александровна — научный сотрудник гепатологического отделения.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Natalia A. Barsukova — Researcher of the Hepatological Department.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">Kononat@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-1755-0021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арапова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Arapova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арапова Мария Валерьевна — врач-гастроэнтеролог.</p><p>125008, Москва, ул. Большая Академическая, 39, корп. 3</p></bio><bio xml:lang="en"><p>Mariya V. Arapova — Gastroenterologist.</p><p>125008, Moscow, Bolshaya Akademicheskaya str., 39, build. 3</p></bio><email xlink:type="simple">arapova.mv@ums-03.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-0218-2941</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исаева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Isaeva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Исаева Екатерина Андреевна — научный сотрудник гепатологического отделения.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Ekaterina A. Isaeva — Researcher of the Hepatological Department.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">adamantas@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2311-0002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коблов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Koblov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коблов Сергей Вячеславович — кандидат медицинских наук, врач-гастроэнтеролог гепатологического отделения.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Sergei V. Koblov — Cand. Sci. (Med.), Gastroenterologist of the Hepatological Department.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">koblov17@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4828-6338</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калашников</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalashnikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калашников Михаил Владиславович — научный сотрудник, врач-гастроэнтеролог гепатологического отделения, МОНИКИ им. М.Ф. Владимирского; врач-терапевт Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Mikhail V. Kalashnikov — Researcher of the Hepatological Department, MRRCI (“MONIKI”); Physician of the E.M. Tareev Clinic of Rheumatology, Nephrology and Occupational Pathology, I.M.   Sechenov FMSMU (Sechenov University).</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">mk1408@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8893-4156</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzymina</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьмина Ольга Сергеевна — кандидат медицинских наук, врач-гастроэнтеролог гепатологического отделения.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Olga S. Kuzmina — Cand. Sci. (Med.), Gastroenterologist of the Hepatological Department.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">ok-1975@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-2994-6093</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демьянов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Demyanov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Демьянов Александр Юрьевич — научный сотрудник гепатологического отделения.</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Alexander Yu. Demyanov — Researcher of the Hepatological Department.</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">ademyanov1@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5041-3466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буеверов</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bueverov</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Буеверов Алексей Олегович — доктор медицинских наук, профессор, ведущий научный сотрудник гепатологического отделения, МОНИКИ им. М.Ф. Владимирского; профессор кафедры медико-социальной экспертизы, неотложной и поликлинической терапии, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>129110, Москва, ул. Щепкина, 61/2, корп. 8</p></bio><bio xml:lang="en"><p>Alexey O. Bueverov — Dr. Sci. (Med)., Professor, Leading Researcher of the Hepatological Department, MRRCI (“MONIKI”); Professor of the Department of Medical and Social Expertise, Emergency and Outpatient Therapy, I.M. Sechenov FMSMU (Sechenov University).</p><p>129110, Moscow, Shchepkina str., 61/2, build. 8</p></bio><email xlink:type="simple">bcl72@yandex.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6114-564X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маев</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maev</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маев Игорь Вениаминович — доктор медицинских наук, академик РАН, профессор, заведующий кафедрой пропедевтики внутренних болезней и гастроэнтерологии.</p><p>127473, Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Igor V. Maev — Dr. Sci. (Med)., Professor, Academician of the Russian Academy of Medical Sciences, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology.</p><p>127473, Moscow, Delegatskaya str., 20, build. 1</p></bio><email xlink:type="simple">ProRekt-02@msmsu.ru</email><xref ref-type="aff" rid="aff-6"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ); ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской Федерации; ООО «Центр таргетной терапии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute (“MONIKI”); Russian University of Medicine; OOO Target Therapy Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ООО «Центр таргетной терапии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>OOO Target Therapy Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ООО «Инвитро-Москва»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>OOO Invitro-Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute (“MONIKI”)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ); ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute (“MONIKI”); I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>04</day><month>12</month><year>2024</year></pub-date><volume>34</volume><issue>5</issue><fpage>40</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богомолов П.О., Шуб Н.А., Гасилова Н.А., Белякова А.А., Лиджиева Ц.Г., Кондрашева Е.А., Барсукова Н.А., Арапова М.В., Исаева Е.А., Коблов С.В., Калашников М.В., Кузьмина О.С., Демьянов А.Ю., Буеверов А.О., Маев И.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Богомолов П.О., Шуб Н.А., Гасилова Н.А., Белякова А.А., Лиджиева Ц.Г., Кондрашева Е.А., Барсукова Н.А., Арапова М.В., Исаева Е.А., Коблов С.В., Калашников М.В., Кузьмина О.С., Демьянов А.Ю., Буеверов А.О., Маев И.В.</copyright-holder><copyright-holder xml:lang="en">Bogomolov P.O., Shub N.A., Gasilova N.A., Belyakova A.A., Lidzhieva T.G., Kondrasheva E.A., Barsukova N.A., Arapova M.V., Isaeva E.A., Koblov S.V., Kalashnikov M.V., Kuzymina O.S., Demyanov A.Y., Bueverov A.O., Maev I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/1355">https://www.gastro-j.ru/jour/article/view/1355</self-uri><abstract><sec><title>Цель</title><p>Цель: оценить значение положительного результата полимеразной цепной реакции на РНК вируса гепатита D (HDV РНК) в биоптате печени больных хроническим гепатитом D (ХГD) после завершения противовирусной терапии (ПВТ) в качестве предиктора рецидива инфекции.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование был включен 21 пациент с ХГD, которые получали комбинированную ПВТ пэгинтерфероном альфа и булевиртидом в течение 48 недель и продолжали монотерапию булевиртидом в течение 48–96 недель, то есть общая продолжительность противовирусной терапии составила 96–144 недели. У всех пациентов HDV РНК перестала определяться в сыворотке крови через 24–96 недель от начала лечения при сохранении авиремии не менее 48 недель до завершения противовирусной терапии. В конце лечения всем пациентам была выполнена биопсия печени с определением HDV РНК в ткани печени.</p></sec><sec><title>Результаты</title><p>Результаты. Из 21 пациента с сохранением полного вирусологического ответа (негативный результат полимеразной цепной реакции на HDV РНК) в сыворотке у 8 (38 %) в ткани печени была обнаружена HDV РНК, то есть не достигнут тканевой вирусологический ответ. У всех 8 пациентов в течение 24 недель после прекращения ПВТ наблюдался рецидив ХГD.</p></sec><sec><title>Выводы</title><p>Выводы. У пациентов с ХГD с полным сывороточным вирусологическим ответом отсутствие тканевого вирусологического ответа (обнаружение HDV РНК в биоптате печени) является предиктором рецидива, что служит основанием для продолжения ПВТ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of infection relapse.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 21 patients with CHD who received combined AVT with peginterferon alpha and bulevirtide for 48 weeks, followed by bulevirtide monotherapy for 48–96 weeks, making the total duration of antiviral therapy 96–144 weeks. In all patients HDV RNA became undetectable in serum 24–96 weeks from the start of treatment, with aviremia maintained for at least 48 weeks until the end of AVT. At the end of treatment, all patients underwent liver biopsy to detect HDV RNA in liver tissue.</p></sec><sec><title>Results</title><p>Results. Out of 21 patients with sustained complete virological response (negative polymerase chain reaction result for HDV RNA in serum), 8 (38 %) had HDV RNA detected in liver tissue, indicating that a tissue virological response was not achieved. All 8 patients experienced a relapse of CHD within 24 weeks after discontinuing AVT.</p></sec><sec><title>Conclusions</title><p>Conclusions. In patients with chronic hepatitis D who have achieved a complete virological response in serum, the absence of a virological response in liver tissue (detection of HDV RNA in liver biopsy) is a predictor of relapse, providing a rationale for the continuation of antiviral therapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический гепатит D</kwd><kwd>противовирусная терапия</kwd><kwd>булевиртид</kwd><kwd>биопсия печени</kwd><kwd>полный вирусологический ответ</kwd><kwd>тканевой вирусологический ответ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic hepatitis D</kwd><kwd>antiviral therapy</kwd><kwd>bulevirtide</kwd><kwd>liver biopsy</kwd><kwd>complete virological response</kwd><kwd>tissue virological response</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kamal H., Westman G., Falconer K., Dube A.-S., Weiland O., Haverinen S., et al. Long-term study of hepati tis delta virus infection at secondary care centers: The impact of viremia on liver-related outcomes. Hepatology. 2020;72(4):1177–90. DOI: 10.1002/hep.31214</mixed-citation><mixed-citation xml:lang="en">Kamal H., Westman G., Falconer K., Dube A.-S., Weiland O., Haverinen S., et al. Long-term study of hepati tis delta virus infection at secondary care centers: The impact of viremia on liver-related outcomes. Hepatology. 2020;72(4):1177–90. DOI: 10.1002/hep.31214</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Urban S., Neumann-Haefelin C., Lampertico P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782–94. DOI: 10.1136/gutjnl-2020-323888</mixed-citation><mixed-citation xml:lang="en">Urban S., Neumann-Haefelin C., Lampertico P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782–94. DOI: 10.1136/gutjnl-2020-323888</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sausen D.G., Shechter O., Bietsch W., Shi Z., Mil ler S.M., Gallo E.O., et al. Hepatitis B and hepatitis D viruses: A comprehensive update with an immunological focus. Int J Mol Sci. 2022;23(24):15973. DOI: 10.3390/ijms232415973</mixed-citation><mixed-citation xml:lang="en">Sausen D.G., Shechter O., Bietsch W., Shi Z., Mil ler S.M., Gallo E.O., et al. Hepatitis B and hepatitis D viruses: A comprehensive update with an immunological focus. Int J Mol Sci. 2022;23(24):15973. DOI: 10.3390/ijms232415973</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lombardo D., Franzè M.S., Caminiti G., Pollicino T. Hepatitis delta virus and hepatocellular carcinoma. Pathogens. 2024;13(5):362. DOI: 10.3390/pathogens13050362</mixed-citation><mixed-citation xml:lang="en">Lombardo D., Franzè M.S., Caminiti G., Pollicino T. Hepatitis delta virus and hepatocellular carcinoma. Pathogens. 2024;13(5):362. DOI: 10.3390/pathogens13050362</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Negro F., Lok A.S. Hepatitis D: A review. JAMA. 2023;330(24):2376–87. DOI: 10.1001/jama.2023.23242</mixed-citation><mixed-citation xml:lang="en">Negro F., Lok A.S. Hepatitis D: A review. JAMA. 2023;330(24):2376–87. DOI: 10.1001/jama.2023.23242</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Stockdale A.J., Kreuels B., Henrion M.Y.R., Gi orgi E., Kyomuhangi I., Martel C., et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. DOI: 10.1016/j.jhep.2020.04.008</mixed-citation><mixed-citation xml:lang="en">Stockdale A.J., Kreuels B., Henrion M.Y.R., Gi orgi E., Kyomuhangi I., Martel C., et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. DOI: 10.1016/j.jhep.2020.04.008</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Miao Z., Zhang S., Ou X., Li S., Ma Z., Wang W., et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87. DOI: 10.1093/infdis/jiz633</mixed-citation><mixed-citation xml:lang="en">Miao Z., Zhang S., Ou X., Li S., Ma Z., Wang W., et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87. DOI: 10.1093/infdis/jiz633</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">McNair A.N., Cheng D., Monjardino J., Thomas H.C., Kerr I.M. Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol. 1994;75(Pt 6):1371–8. DOI: 10.1099/0022-1317-75-6-1371</mixed-citation><mixed-citation xml:lang="en">McNair A.N., Cheng D., Monjardino J., Thomas H.C., Kerr I.M. Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol. 1994;75(Pt 6):1371–8. DOI: 10.1099/0022-1317-75-6-1371</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Abdrakhman A., Ashimkhanova A., Almawi W.Y. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021;185:104995. DOI: 10.1016/j.antiviral.2020.104995</mixed-citation><mixed-citation xml:lang="en">Abdrakhman A., Ashimkhanova A., Almawi W.Y. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021;185:104995. DOI: 10.1016/j.antiviral.2020.104995</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bremer B., Anastasiou O.E., Hardtke S., Caruntu F.A., Curescu M.G., Yalcin K., et al. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver Int. 2021;41(2):295–9. DOI: 10.1111/liv.14740</mixed-citation><mixed-citation xml:lang="en">Bremer B., Anastasiou O.E., Hardtke S., Caruntu F.A., Curescu M.G., Yalcin K., et al. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver Int. 2021;41(2):295–9. DOI: 10.1111/liv.14740</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wedemeyer H., Yurdaydìn C., Dalekos G.N., Erhardt A., Çakaloğlu Y., Değertekin H., et al.; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. DOI: 10.1056/NEJMoa0912696</mixed-citation><mixed-citation xml:lang="en">Wedemeyer H., Yurdaydìn C., Dalekos G.N., Erhardt A., Çakaloğlu Y., Değertekin H., et al.; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. DOI: 10.1056/NEJMoa0912696</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brancaccio G., Fasano M., Grossi A., Santantonio T.A., Gaeta G.B. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071–6. DOI: 10.1111/apt.15188</mixed-citation><mixed-citation xml:lang="en">Brancaccio G., Fasano M., Grossi A., Santantonio T.A., Gaeta G.B. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071–6. DOI: 10.1111/apt.15188</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Urban S., Bartenschlager R., Kubitz R., Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64. DOI: 10.1053/j.gastro.2014.04.030</mixed-citation><mixed-citation xml:lang="en">Urban S., Bartenschlager R., Kubitz R., Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64. DOI: 10.1053/j.gastro.2014.04.030</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Blank A., Eidam A., Haag M., Hohmann N., Burhenne J., Schwab M., et al. The NTCP-inhibitor Myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther. 2018;103(2):341–8. DOI: 10.1002/cpt.744</mixed-citation><mixed-citation xml:lang="en">Blank A., Eidam A., Haag M., Hohmann N., Burhenne J., Schwab M., et al. The NTCP-inhibitor Myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther. 2018;103(2):341–8. DOI: 10.1002/cpt.744</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bogomolov P., Alexandrov A., Voronkova N., Macievich M., Kokina K., Petrachenkova M., et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8. DOI: 10.1016/j.jhep.2016.04.016</mixed-citation><mixed-citation xml:lang="en">Bogomolov P., Alexandrov A., Voronkova N., Macievich M., Kokina K., Petrachenkova M., et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8. DOI: 10.1016/j.jhep.2016.04.016</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dietz-Fricke C., Tacke F., Zöllner C., Demir M., Schmidt H.H., Schramm C., et al. Treating hepatitis D with bulevirtide — real-world experience from 114 patients. JHEP Rep. 2023;5(4):100686. DOI: 10.1016/j.jhepr.2023.100686</mixed-citation><mixed-citation xml:lang="en">Dietz-Fricke C., Tacke F., Zöllner C., Demir M., Schmidt H.H., Schramm C., et al. Treating hepatitis D with bulevirtide — real-world experience from 114 patients. JHEP Rep. 2023;5(4):100686. DOI: 10.1016/j.jhepr.2023.100686</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Allweiss L., Volmari A., Suri V., Wallin J.J., Flaherty J.F., Manuilov D., et al. Blocking viral en try with bulevirtide reduces the number of HDV infected hepatocytes in human liver biopsies. J Hepatol. 2024;80(6):882–91. DOI: 10.1016/j.jhep.2024.01.035</mixed-citation><mixed-citation xml:lang="en">Allweiss L., Volmari A., Suri V., Wallin J.J., Flaherty J.F., Manuilov D., et al. Blocking viral en try with bulevirtide reduces the number of HDV infected hepatocytes in human liver biopsies. J Hepatol. 2024;80(6):882–91. DOI: 10.1016/j.jhep.2024.01.035</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wedemeyer H., Leus M., Battersby T.R., Glenn J., Gordien E., Kamili S., et al. HDV RNA assays: Performance characteristics, clinical utility and challenges. Hepatology. 2023;10.1097/HEP.0000000000000584. DOI: 10.1097/HEP.0000000000000584</mixed-citation><mixed-citation xml:lang="en">Wedemeyer H., Leus M., Battersby T.R., Glenn J., Gordien E., Kamili S., et al. HDV RNA assays: Performance characteristics, clinical utility and challenges. Hepatology. 2023;10.1097/HEP.0000000000000584. DOI: 10.1097/HEP.0000000000000584</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433– 60. DOI: 10.1016/j.jhep.2023.05.001</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433– 60. DOI: 10.1016/j.jhep.2023.05.001</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Queiroz J.A., Roca T.P., Souza R.B., Fellype L., Alves de Souza L.F., Passos-Silva A., et al. Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus. Sci Rep. 2023;13(1):12073. DOI: 10.1038/s41598-023-37756-z</mixed-citation><mixed-citation xml:lang="en">Queiroz J.A., Roca T.P., Souza R.B., Fellype L., Alves de Souza L.F., Passos-Silva A., et al. Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus. Sci Rep. 2023;13(1):12073. DOI: 10.1038/s41598-023-37756-z</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jachs M., Panzer M., Hartl L., Schwarz M., Bal car L., Camp J.V., et al. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023;5(8):100751. DOI: 10.1016/j.jhepr.2023.100751</mixed-citation><mixed-citation xml:lang="en">Jachs M., Panzer M., Hartl L., Schwarz M., Bal car L., Camp J.V., et al. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023;5(8):100751. DOI: 10.1016/j.jhepr.2023.100751</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
